In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Surface Oncology closes $35mm Series A

Executive Summary

Surface Oncology (cancer immunotherapies) raised $35mm through its Series A round. Seed investor Atlas Venture led and was joined by Fidelity Biosciences, Lilly Ventures, New Enterprise Associates (NEA), Amgen Ventures, Novartis Institutes for Biomedical Research, and the former head of R&D at BMS Dr. Elliott Sigal, who joins the company’s scientific advisory board.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies